<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227617</url>
  </required_header>
  <id_info>
    <org_study_id>04458</org_study_id>
    <secondary_id>NCI-2011-01214</secondary_id>
    <nct_id>NCT00227617</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors</brief_title>
  <official_title>A Pilot Study of FOLFOX in Combination With Bevacizumab in Patients With Advanced Neuroendocrine Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor&#xD;
      growth in different ways. Some block the ability of tumor cells to grow and spread. Others&#xD;
      find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab&#xD;
      may also stop the growth of neuroendocrine tumors by blocking blood flow to the tumor. Giving&#xD;
      combination chemotherapy together with bevacizumab may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of giving combination&#xD;
      chemotherapy together with bevacizumab and to see how well it works in treating patients with&#xD;
      advanced neuroendocrine tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of fluorouracil, leucovorin calcium, and oxaliplatin (FOLFOX) with&#xD;
           bevacizumab in patients with advanced neuroendocrine tumors.&#xD;
&#xD;
        -  Determine the best overall response rate in patients treated with this regimen.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the time to treatment failure and progression in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the biochemical marker response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study. Patients are stratified according to tumor type&#xD;
      (carcinoid vs islet cell vs poorly differentiated neuroendocrine).&#xD;
&#xD;
      Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1&#xD;
      and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients also receive&#xD;
      bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 14 days for up to 26&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 39-102 patients (13-34 per stratum) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">June 8, 2005</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Discontinuation Due to Adverse Events Possibly Related to Study Treatment</measure>
    <time_frame>From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years</time_frame>
    <description>Rates of discontinuation were calculated as counts and percentages of patients whom discontinued treatment due to adverse events possibly related to the investigational treatments not including neuropathy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Best Objective Response</measure>
    <time_frame>From Baseline until disease progression, up to 8 years</time_frame>
    <description>Best Objective Response by RECIST with Exact 95% Binomial CIs across all tumor types. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria Target lesions response + Non-Target lesions response + Evaluation of non-target lesions (Yes / No) = Overall response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years</time_frame>
    <description>Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Median Survival</measure>
    <time_frame>until death, up to 8 years</time_frame>
    <description>The overall survival is defined as the time from baseline until death (Carcinoid, PNET, PDNEC) using Kaplan-Meier Survival analysis methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Time to Treatment Failure</measure>
    <time_frame>From initial complete or partial response to disease progression, up to 8 years</time_frame>
    <description>Time to treatment failure is defined as the time from the initial complete or partial response to documented disease progression or death (whichever occurs first) across treatment groups and inclusive of drug holidays and estimated using Kaplan-Meier survival analysis methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Marker Response</measure>
    <time_frame>From Baseline until end of treatment, up to 8 years</time_frame>
    <description>Biochemical marker response is defined as &gt;=50% reduction in marker or hormone(s) that were elevated at baseline. Markers/hormones tested are: Chromagranin A (CGA), 5-HIAA, Insulin, Proinsulin, C-peptide, Pancreatic polypeptide, Gastrin, Glucagon, and Vasointestinal Peptide.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Gastrointestinal Carcinoid Tumor</condition>
  <condition>Islet Cell Tumor</condition>
  <condition>Lung Cancer</condition>
  <condition>Neoplastic Syndrome</condition>
  <condition>Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>FOLFOX with Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting on Day 1, administered every two weeks:&#xD;
5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.</description>
    <arm_group_label>FOLFOX with Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.</description>
    <arm_group_label>FOLFOX with Bevacizumab</arm_group_label>
    <other_name>5-FU</other_name>
    <other_name>Adrucil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>200mg/m2 IV q2 wk on day 1 over a 2-hour period.</description>
    <arm_group_label>FOLFOX with Bevacizumab</arm_group_label>
    <other_name>Folinic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>200mg/m2 IV q 2 wk on day 1 over a 2-hour period</description>
    <arm_group_label>FOLFOX with Bevacizumab</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed neuroendocrine tumor (NET)&#xD;
&#xD;
               -  Carcinoid at any site, with or without carcinoid syndrome&#xD;
&#xD;
               -  Pancreatic islet cell tumor&#xD;
&#xD;
                    -  Prior streptozocin-based therapy not required&#xD;
&#xD;
               -  Poorly differentiated NET of any primary site (this arm closed to accrual May&#xD;
                  2009)&#xD;
&#xD;
                    -  Progression with prior treatment with cisplatin-, or carboplatin-based&#xD;
                       chemotherapy required (unless contraindicated)&#xD;
&#xD;
          -  The following tumors are not allowed:&#xD;
&#xD;
               -  Endocrine organ carcinoma&#xD;
&#xD;
               -  Adrenal gland malignancies&#xD;
&#xD;
               -  Thyroid carcinoma of any histology&#xD;
&#xD;
               -  Pheochromocytoma/paraganglioma&#xD;
&#xD;
          -  Advanced disease&#xD;
&#xD;
               -  Disease not amenable to surgery, radiotherapy, or combined modality therapy with&#xD;
                  curative intent&#xD;
&#xD;
          -  Radiologically or clinically confirmed progressive disease&#xD;
&#xD;
               -  At least 25% increase in radiologically or clinically measurable disease&#xD;
&#xD;
               -  At least 20% increase in the longest diameter (LD) of any previously documented&#xD;
                  lesion&#xD;
&#xD;
               -  Increase in the sum of the LD of multiple lesions in aggregate of 20%, OR&#xD;
                  appearance of new lesions OR deterioration in clinical status&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional&#xD;
                  radiographic techniques OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
                    -  Ultrasound or positron-emission tomography alone not sufficient&#xD;
&#xD;
               -  Bone lesions, ascites, peritoneal carcinomatosis, pleural or pericardial&#xD;
                  effusion, and irradiated lesions are not considered measurable disease&#xD;
&#xD;
          -  Primary tumors of the pancreas should not invade adjacent organs (e.g., stomach or&#xD;
             duodenum)&#xD;
&#xD;
          -  No history or evidence of brain or leptomeningeal disease (baseline CNS imaging&#xD;
             required if clinical suspicion of CNS metastases)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No history of hemoptysis or bleeding diathesis&#xD;
&#xD;
          -  No coagulopathy unrelated to therapeutic anticoagulation&#xD;
&#xD;
          -  No significant bleeding events within the past 6 months unless the source of the&#xD;
             bleeding has been resected&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if due to liver metastases)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 2 mg/dL&#xD;
&#xD;
          -  Protein ≤ 1+ OR&#xD;
&#xD;
          -  Protein &lt; 1 gm on 24-hour urine collection&#xD;
&#xD;
          -  Urine protein:creatinine ratio &lt; 1.0&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  History of thromboembolic condition allowed provided patient is on therapeutic&#xD;
             anticoagulation at a stable dose for ≥ 4 weeks&#xD;
&#xD;
               -  Concurrent daily prophylactic aspirin (&lt; 325 mg/day) allowed&#xD;
&#xD;
          -  No uncontrolled hypertension, myocardial infarction, clinically significant peripheral&#xD;
             arterial ischemia, visceral arterial ischemia or angina within the past 6 months&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past&#xD;
             12 months&#xD;
&#xD;
          -  No history of peripheral vascular disease ≥ grade 2&#xD;
&#xD;
          -  No history New York Heart Association class II-IV congestive heart failure&#xD;
&#xD;
          -  Blood pressure ≤ 160/90 mm Hg&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within&#xD;
             the past 6 months&#xD;
&#xD;
          -  No predisposing uncontrolled small bowel or colonic disorder&#xD;
&#xD;
               -  Baseline disease-related diarrhea allowed if symptoms are stable and&#xD;
                  well-characterized (i.e., # stools/day stable)&#xD;
&#xD;
          -  No gastric or esophageal varices&#xD;
&#xD;
          -  No gastroduodenal ulcers determined to be active by endoscopy&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No interstitial pneumonia or extensive and symptomatic interstitial fibrosis&#xD;
&#xD;
          -  No lung tumor in close proximity to a major vessel, or with associated cavitation&#xD;
&#xD;
          -  No pleural effusion or ascites that causes ≥ grade 2 dyspnea&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for at least 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No currently active second malignancy other than, non-melanoma skin cancer or&#xD;
             carcinoma in situ&#xD;
&#xD;
               -  Patients are not considered to have a currently active malignancy if they have&#xD;
                  completed therapy and are considered by their physician to be at ≤ 30% risk for&#xD;
                  relapse&#xD;
&#xD;
          -  No known hypersensitivity reaction attributed to study drugs or to compounds of&#xD;
             similar chemical or biological composition&#xD;
&#xD;
          -  No symptomatic peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No other severe disease or comorbidity that would preclude study participation&#xD;
&#xD;
          -  No medically uncontrolled seizures&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No serious non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other severe, concurrent disease, infection, or co-morbidity that in the judgement&#xD;
             of the investigator would constitute a hazard for study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Recovered from prior cytokine therapy&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  No prior tyrosine kinase inhibitors or anti-vascular endothelial growth factor (VEGF)&#xD;
             angiogenic inhibitors&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior oxaliplatin&#xD;
&#xD;
          -  Prior chemoembolization therapy allowed provided it did not affect areas of measurable&#xD;
             disease&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior and concurrent somatostatin analogs allowed for symptomatic control and/or&#xD;
             control of hormone hypersecretion only provided treatment was initiated &gt; 3 months&#xD;
             prior to study entry&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
               -  Prior radiotherapy must not affect areas of measurable disease&#xD;
&#xD;
          -  No concurrent radiotherapy to only site of measurable disease&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Recovered from prior surgery&#xD;
&#xD;
          -  Prior cryotherapy allowed provided it did not affect areas of measurable disease&#xD;
&#xD;
          -  At least 28 days since prior major surgical procedure or open biopsy&#xD;
&#xD;
          -  At least 7 days since minor surgical procedure, fine-needle aspirations, or core&#xD;
             biopsy&#xD;
&#xD;
          -  No prior organ allograft&#xD;
&#xD;
          -  No concurrent major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior participation in an experimental drug study&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No halogenated antiviral agents&#xD;
&#xD;
          -  Concurrent antiplatelet agents allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily K. Bergsland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <results_first_submitted>August 7, 2019</results_first_submitted>
  <results_first_submitted_qc>December 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 26, 2019</results_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>pulmonary carcinoid tumor</keyword>
  <keyword>gastrinoma</keyword>
  <keyword>insulinoma</keyword>
  <keyword>WDHA syndrome</keyword>
  <keyword>glucagonoma</keyword>
  <keyword>pancreatic polypeptide tumor</keyword>
  <keyword>somatostatinoma</keyword>
  <keyword>recurrent islet cell carcinoma</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Carcinoid Tumor</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Simon 2-stage design: 13 patients in stage 1. If at least 2 objective tumor responses were observed by 12 cycles of therapy, the cohort was to be expanded to enroll a total of 39 treated patients.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Carcinoid</title>
          <description>Starting on Day 1, administered every two weeks:&#xD;
Leucovorin: 200 mg/ m2; over 2 hours&#xD;
Oxaliplatin : 85 mg/m2; over 2 hours&#xD;
followed by 5-fluorouracil (5-FU): 2400 mg/ m2 CIV; over 46-48 hours&#xD;
Bevacizumab: 5 mg/kg IV&#xD;
5-FU bolus was permanently dropped after nearly all of the first 13 patients required a dose reduction for toxicity:&#xD;
3 in carcinoid&#xD;
10 in PNET</description>
        </group>
        <group group_id="P2">
          <title>PNET</title>
          <description>Starting on Day 1, administered every two weeks:&#xD;
Leucovorin: 200 mg/ m2; over 2 hours&#xD;
Oxaliplatin : 85 mg/m2; over 2 hours&#xD;
followed by 5-fluorouracil (5-FU): 2400 mg/ m2 CIV; over 46-48 hours&#xD;
Bevacizumab: 5 mg/kg IV&#xD;
5-FU bolus was permanently dropped after nearly all of the first 13 patients required a dose reduction for toxicity:&#xD;
3 in carcinoid&#xD;
10 in PNET</description>
        </group>
        <group group_id="P3">
          <title>Poorly Differentiated Neuroendocrine Carcinomas (PDNEC)</title>
          <description>Starting on Day 1, administered every two weeks:&#xD;
Leucovorin: 200 mg/ m2; over 2 hours&#xD;
Oxaliplatin : 85 mg/m2; over 2 hours&#xD;
followed by 5-fluorouracil (5-FU): 2400 mg/ m2 CIV; over 46-48 hours&#xD;
Bevacizumab: 5 mg/kg IV&#xD;
5-FU bolus was permanently dropped after nearly all of the first 13 patients required a dose reduction for toxicity:&#xD;
3 in carcinoid&#xD;
10 in PNET</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Stage 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patient data was migrated at time of close to accrual and the treatment arm information was not included in data migration. As such baseline data for patients with Carcinoid Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Poorly Differentiated Neuroendocrine Carcinoma data has been reported across treatment arms</population>
      <group_list>
        <group group_id="B1">
          <title>Combined Neuroendocrine Tumors</title>
          <description>Patients with Carcinoid Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, and Poorly Differentiated Neuroendocrine Carcinoma enrolled on the protocol</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>40-49 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-69 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-79 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-89 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Discontinuation Due to Adverse Events Possibly Related to Study Treatment</title>
        <description>Rates of discontinuation were calculated as counts and percentages of patients whom discontinued treatment due to adverse events possibly related to the investigational treatments not including neuropathy.</description>
        <time_frame>From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years</time_frame>
        <population>Study terminated early due to low accrual. UCSF moved its clinical research database from Velos to OnCore in July 2010 and some of the data for this study was not transferred. Results reported accurate to date</population>
        <group_list>
          <group group_id="O1">
            <title>Carcinoid</title>
            <description>Starting on Day 1, administered every two weeks:&#xD;
5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes&#xD;
bevacizumab: 5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.&#xD;
5-fluorouracil: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.&#xD;
leucovorin: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.&#xD;
oxaliplatin: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period</description>
          </group>
          <group group_id="O2">
            <title>PNET</title>
            <description>Starting on Day 1, administered every two weeks:&#xD;
5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes&#xD;
bevacizumab: 5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.&#xD;
5-fluorouracil: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.&#xD;
leucovorin: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.&#xD;
oxaliplatin: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period</description>
          </group>
          <group group_id="O3">
            <title>PDNEC</title>
            <description>Starting on Day 1, administered every two weeks:&#xD;
5-fluorouracil: 2400 mg/ m2 CIV; over 46-48 hours Leucovorin: 200 mg/ m2; over 2 hours Oxaliplatin : 85 mg/m2; over 2 hours Bevacizumab: 5 mg/kg IV over 30-90 minutes&#xD;
bevacizumab: 5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.&#xD;
5-fluorouracil: 2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.&#xD;
leucovorin: 200mg/m2 IV q2 wk on day 1 over a 2-hour period.&#xD;
oxaliplatin: 200mg/m2 IV q 2 wk on day 1 over a 2-hour period</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Discontinuation Due to Adverse Events Possibly Related to Study Treatment</title>
          <description>Rates of discontinuation were calculated as counts and percentages of patients whom discontinued treatment due to adverse events possibly related to the investigational treatments not including neuropathy.</description>
          <population>Study terminated early due to low accrual. UCSF moved its clinical research database from Velos to OnCore in July 2010 and some of the data for this study was not transferred. Results reported accurate to date</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Best Objective Response</title>
        <description>Best Objective Response by RECIST with Exact 95% Binomial CIs across all tumor types. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria Target lesions response + Non-Target lesions response + Evaluation of non-target lesions (Yes / No) = Overall response</description>
        <time_frame>From Baseline until disease progression, up to 8 years</time_frame>
        <population>Intent-to-Treat population used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Neuroendocrine Tumors</title>
            <description>Patients with Carcinoid Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Poorly Differentiated Neuroendocrine Carcinoma who received at least one treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Best Objective Response</title>
          <description>Best Objective Response by RECIST with Exact 95% Binomial CIs across all tumor types. The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria Target lesions response + Non-Target lesions response + Evaluation of non-target lesions (Yes / No) = Overall response</description>
          <population>Intent-to-Treat population used for analysis</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unevaluable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" lower_limit="0" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="16" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64" lower_limit="46" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first).</description>
        <time_frame>From beginning of treatment up to 18 months; Post-study survival follow-up up to 8 years</time_frame>
        <population>A reliable median and 95% confidence interval for time to progression could not be computed for participants with Poorly Differentiated Neuroendocrine Carcinoma (PDNEC) due to the insufficient number of participants with this condition (N=2)</population>
        <group_list>
          <group group_id="O1">
            <title>Carcinoid</title>
            <description>Carcinoid Neuroendocrine Tumors</description>
          </group>
          <group group_id="O2">
            <title>PNET</title>
            <description>Pancreatic Neuroendocrine Tumors</description>
          </group>
          <group group_id="O3">
            <title>PDNEC</title>
            <description>Poorly Differentiated Neuroendocrine carcinoma</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Time to disease progression will be defined as the time from baseline until documented disease progression or death (whichever occurs first).</description>
          <population>A reliable median and 95% confidence interval for time to progression could not be computed for participants with Poorly Differentiated Neuroendocrine Carcinoma (PDNEC) due to the insufficient number of participants with this condition (N=2)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" lower_limit="9.9" upper_limit="29.9"/>
                    <measurement group_id="O2" value="21" lower_limit="7.4" upper_limit="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Median Survival</title>
        <description>The overall survival is defined as the time from baseline until death (Carcinoid, PNET, PDNEC) using Kaplan-Meier Survival analysis methods.</description>
        <time_frame>until death, up to 8 years</time_frame>
        <population>Intent-to-Treat population used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Neuroendocrine Tumors</title>
            <description>Patients with Carcinoid Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Poorly Differentiated Neuroendocrine Carcinoma who received at least one treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Median Survival</title>
          <description>The overall survival is defined as the time from baseline until death (Carcinoid, PNET, PDNEC) using Kaplan-Meier Survival analysis methods.</description>
          <population>Intent-to-Treat population used for analysis</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="23.3" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Time to Treatment Failure</title>
        <description>Time to treatment failure is defined as the time from the initial complete or partial response to documented disease progression or death (whichever occurs first) across treatment groups and inclusive of drug holidays and estimated using Kaplan-Meier survival analysis methods</description>
        <time_frame>From initial complete or partial response to disease progression, up to 8 years</time_frame>
        <population>Intent-to-Treat population used for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Combined Neuroendocrine Tumors</title>
            <description>Patients with Carcinoid Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, Poorly Differentiated Neuroendocrine Carcinoma who received at least one treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Time to Treatment Failure</title>
          <description>Time to treatment failure is defined as the time from the initial complete or partial response to documented disease progression or death (whichever occurs first) across treatment groups and inclusive of drug holidays and estimated using Kaplan-Meier survival analysis methods</description>
          <population>Intent-to-Treat population used for analysis</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="6.5" upper_limit="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Marker Response</title>
        <description>Biochemical marker response is defined as &gt;=50% reduction in marker or hormone(s) that were elevated at baseline. Markers/hormones tested are: Chromagranin A (CGA), 5-HIAA, Insulin, Proinsulin, C-peptide, Pancreatic polypeptide, Gastrin, Glucagon, and Vasointestinal Peptide.</description>
        <time_frame>From Baseline until end of treatment, up to 8 years</time_frame>
        <population>Percentages of participants who met criteria of a biochemical marker response are also displayed</population>
        <group_list>
          <group group_id="O1">
            <title>Carcinoid</title>
            <description>Carcinoid Neuroendocrine Tumors</description>
          </group>
          <group group_id="O2">
            <title>PNET</title>
            <description>Pancreatic Neuroendocrine Tumors</description>
          </group>
          <group group_id="O3">
            <title>PDNEC</title>
            <description>Poorly differentiated neuroendocrine carcinoma (PDNEC)</description>
          </group>
          <group group_id="O4">
            <title>All Neuroendocrine Tumors</title>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Marker Response</title>
          <description>Biochemical marker response is defined as &gt;=50% reduction in marker or hormone(s) that were elevated at baseline. Markers/hormones tested are: Chromagranin A (CGA), 5-HIAA, Insulin, Proinsulin, C-peptide, Pancreatic polypeptide, Gastrin, Glucagon, and Vasointestinal Peptide.</description>
          <population>Percentages of participants who met criteria of a biochemical marker response are also displayed</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chromogranin A (CGA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hormone and/or CGA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hormone (not including CGA)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 8 years</time_frame>
      <desc>Data migration issue prevented this data from being reported by treatment arm. Adverse Events grade 3 and higher were not reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Combined Neuroendocrine Tumors</title>
          <description>Patients enrolled on protocol with Carcinoid Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumors, or Poorly Differentiated Neuroendocrine Carcinoma whom received at least one treatment</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MEDRA 10.0">Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Perforation, GI - Small bowel NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ulcer, GI - Duodenum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI- Upper GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Abdomen NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>asthenia, lethargy, malaise</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <description>in the absence of neutropenia, where neutropenia is defined as ANC &lt;1.0 x 10e9/L</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Death not associated with CTCAE term - Disease progression NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <description>(fever of unknown origin without clinically or microbiologically documented infection) (AND&lt;1.0 X 10e9/L, fever &gt;38.5 degrees)</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Infection - Other (specify,__)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Glucose, serum-low (hypoglycemia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain - Back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain - Neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="31" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="12" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="29" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Febrile Neurtropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="17" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="30" subjects_affected="19" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="56" subjects_affected="26" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Perforation, GI - Small bowel NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Ulcer, GI - Duodenum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hemorrhage, GI - Upper GI NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Pain- Abdominal</sub_title>
                <counts group_id="E1" events="34" subjects_affected="15" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="78" subjects_affected="32" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="27" subjects_affected="9" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy: sensory</sub_title>
                <counts group_id="E1" events="144" subjects_affected="34" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed; Technical problems with database migration lead to missing treatment assignment values.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Emily Bergsland</name_or_title>
      <organization>UCSF Helen Diller Family Comprehensive Cancer Center</organization>
      <phone>415-885-7810</phone>
      <email>Emily.Bergsland@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

